Renalytix (LON:RENX) Trading Down 3.4% – Time to Sell?

Renalytix Plc (LON:RENX)’s share price traded down 3.4% during mid-day trading on Wednesday . The stock traded as low as GBX 11 ($0.14) and last traded at GBX 11.11 ($0.14). 181,677 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 344,406 shares. The stock had previously closed at GBX 11.50 ($0.14).

Renalytix Trading Down 3.4 %

The stock has a market capitalization of £18.44 million, a P/E ratio of -46.30 and a beta of 2.10. The business has a 50 day simple moving average of GBX 9.49 and a 200-day simple moving average of GBX 10.27. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53.

Insider Buying and Selling

In related news, insider James Renwick McCullough acquired 25,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of GBX 9 ($0.11) per share, for a total transaction of £2,250 ($2,769.91). Insiders own 35.74% of the company’s stock.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.